New Horizons in ESR1-Mutated Breast Cancer

16 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
The full article for this interview is available on Oncology Data Advisor. Check it out here: https://oncdata.com/imlunestrant-breast-cancer-komal-jhaveri

The FDA approval of imlunestrant marks a pivotal milestone in treating advanced or metastatic breast cancer with ESR1 mutations, which contribute to treatment resistance. Join Dr. Komal Jhaveri, Breast Medical Oncologist at Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment landscape, and the importance of biomarker-driven care.

Learn about imlunestrant’s role as an oral SERD, its benefits in ESR1-mutant tumors, and the promise of future combination therapies.

#BreastCancerAwareness #Imlunestrant #ESR1Mutations #OralSERDs #BreastCancerCare #OncologyInnovation #EMBER3Trial #PrecisionOncology #CancerResearch #PatientOutcomes
Categoria
Oncology
Commenta per primo questo video.

Prossimo